Cargando…

Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies

Detalles Bibliográficos
Autores principales:	Gambacorti-Passerini, Carlo, Ruggeri, Marco, Aroldi, Andrea, Piazza, Rocco, Mazzi, Angela, De Silvestro, Giustina, Krampera, Mauro, Lanza, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896506/ https://www.ncbi.nlm.nih.gov/pubmed/33637468 http://dx.doi.org/10.1016/j.transci.2021.103105

Ejemplares similares

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019
por: Aroldi, Andrea, et al.
Publicado: (2021)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK(+) lymphomas
por: Rindone, Giovanni, et al.
Publicado: (2022)

Caution in using second generation tyrosine kinase inhibitor, especially for first line therapy of chronic myeloid leukemia
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2022)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Humoral and cellular immune response in patients with hematological disorders after two doses of BNT162b2 mRNA COVID‐19 vaccine: A single‐center prospective observational study (NCT05074706)
por: Bossi, Elisa, et al.
Publicado: (2022)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Related donor platelet transfusion improves platelet transfusion refractoriness in hematological patients
por: Zhang, Jing-Cheng, et al.
Publicado: (2023)

High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies
por: Tanasi, Ilaria, et al.
Publicado: (2020)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
por: Zappasodi, Patrizia, et al.
Publicado: (2022)

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia
por: Aroldi, Andrea, et al.
Publicado: (2023)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Granulocyte transfusions in children and adults with hematological malignancies: benefits and controversies
por: Cugno, Chiara, et al.
Publicado: (2015)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

P1056: NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES
por: Sangiorgio, Valentina, et al.
Publicado: (2023)

Analysis of hematologic parameters of donors, patients, and granulocyte concentrates to predict successful granulocyte transfusion
por: Lee, Jong-Mi, et al.
Publicado: (2019)

Red blood cell transfusion in the resuscitation of septic patients with hematological malignancies
por: Mirouse, Adrien, et al.
Publicado: (2017)

Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
por: Ibrahim, Ahmad, et al.
Publicado: (2021)

Unmanipulated haploidentical transplantation for adult patients with hematological malignancies
por: Ruggeri, Annalisa, et al.
Publicado: (2019)

OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Rocco, Piazza, et al.
Publicado: (2017)

Erratum: OncoScore: a novel, Internet-based tool to assess the oncogenic potential of genes
por: Piazza, Rocco, et al.
Publicado: (2017)

CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data
por: Piazza, Rocco, et al.
Publicado: (2013)

Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
por: Nucera, Silvia, et al.
Publicado: (2020)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition
por: Mologni, Luca, et al.
Publicado: (2017)

Risk of hematological malignancy in blood donors: A nationwide cohort study
por: Zhao, Jingcheng, et al.
Publicado: (2020)

Genetic Predisposition to Hematologic Malignancies in Childhood and Adolescence
por: Fabozzi, Francesco, et al.
Publicado: (2023)

Characterization of SARS-CoV-2 Mutational Signatures from 1.5+ Million Raw Sequencing Samples
por: Aroldi, Andrea, et al.
Publicado: (2022)

Safety and Effectiveness of Intensive Treatments Administered Outside the Intensive Care Unit to Hematological Critically Ill Patients: An Intensive Care without Walls Trial
por: Vergnano, Beatrice, et al.
Publicado: (2023)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization
por: Civettini, Ivan, et al.
Publicado: (2023)

ERG Deregulation Induces PIM1 Over-Expression and Aneuploidy in Prostate Epithelial Cells
por: Magistroni, Vera, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_064711kl2edoofbcpftiacr648